Stock PSYB PSYBIO THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages PsyBio Therapeutics Corp. Toronto S.E.

Equities

PSYB

CA5263612098

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie
PsyBio Therapeutics Corp. Announces Executive Changes
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer
PsyBio Therapeutics Announces Retention of Market Maker
PSYO THER : PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization
PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSYB.H Stock
  4. PSYB Stock
  5. News PsyBio Therapeutics Corp.
  6. Other languages